220 related articles for article (PubMed ID: 657108)
1. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
2. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
3. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
4. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
Mavligit GM; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
[TBL] [Abstract][Full Text] [Related]
5. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
[TBL] [Abstract][Full Text] [Related]
6. Intralesional immunotherapy of melanoma with BCG.
Rosenberg SA; Rapp HJ
Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
[TBL] [Abstract][Full Text] [Related]
7. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
Coates AS; Peters M
Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
[TBL] [Abstract][Full Text] [Related]
8. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
Storm FK; Sparks FC; Morton DL
Surg Gynecol Obstet; 1979 Jul; 149(1):17-21. PubMed ID: 451822
[TBL] [Abstract][Full Text] [Related]
9. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
de la Monte SM; Hutchins GM
Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of melanoma with intralesional BCG.
Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
[No Abstract] [Full Text] [Related]
11. Intralesional BCG in the treatment of metastatic malignant melanoma.
Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
[TBL] [Abstract][Full Text] [Related]
12. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
[No Abstract] [Full Text] [Related]
13. Immunotherapy of malignancy in humans. Current status.
Holmes EC; Eilber FR; Morton DL
JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
[TBL] [Abstract][Full Text] [Related]
15. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
17. Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guérin therapy for locally metastatic melanoma.
Cohen MH; Elin RJ; Cohen BJ
Cancer Immunol Immunother; 1991; 32(5):315-24. PubMed ID: 1998973
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
Pinsky CM; Hirshaut Y; Wanebo HJ; Fortner JG; Miké V; Schottenfeld D; Oettgen HF
Ann N Y Acad Sci; 1976; 277(00):187-94. PubMed ID: 1069548
[No Abstract] [Full Text] [Related]
19. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
Lokich JJ; Garnick MB; Legg M
Oncology; 1979; 36(5):236-41. PubMed ID: 481845
[TBL] [Abstract][Full Text] [Related]
20. An in vitro method for assaying sensitivity to 2,4-dinitrochlorobenzene (DNCB) in man.
Whitehead RH; Bolton PM; James SL; Roberts GM
Eur J Cancer (1965); 1974 Nov; 10(11):721-4. PubMed ID: 4469495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
